Document text
Principal Investigator: Lothar Hennighausen
Organization: NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES
Fiscal Year: 2024
Award: $242,663
Funding agency: National Institute of Diabetes and Digestive and Kidney Diseases
In the current reporting period, we published two COVID-19 studies, one on the impact of SARS-CoV-2 variants on alternative splicing of RNAs (PMID: 38414855) and one on computational approached to investigate variant-specific blood transcriptomes (PMID: 38307916).
SARS-CoV-2 infection ranges from asymptomatic to severe with lingering symptomatology in some. When we initiated our studies in the early days of the pandemic, the immune response and prevalence of unrecognized ongoing inflammation to SARS-CoV-2 was not understood. We addressed this question and determined no lingering immunological gene signatures in asymptomatic individuals from one of the original super spreading events in Europe.
As the pandemic progressed, new SARS-CoV-2 variants appeared and there was a need to understand how the immune system responds. Specifically, variants with the E484K spike mutation within the receptor binding domain (RBD), were of particular concern because it enhances escape from neutralizing antibody inhibition in vitro and may be linked with reduced vaccination efficacy. We investigated the immune response to variants carrying this escape mutation and identified a specific gene signature pointing to the preferential activation of the JAK-STA signaling pathway. We also investigated the impact of prior COVID-19 vaccination (BNT162b2) on disease course and found a reduced inflammatory response in patients infected with different variants, including Alpha and Beta.
More recently we investigated the impact of omicron variants (PMID: 36267551). The Omicron variant of SARS-CoV-2 is currently the most prevalent and has produced various sublineages. We have investigated how prior exposure to SARS-CoV-2 affects the immune response to different Omicron sublineages, specifically BA.1 and BA.2. Our study reveals that individuals with no history of COVID-19 exhibit a weaker immune response when infected with the BA.2 sublineage compared to BA.1. The blood samples from individuals with no prior exposure do not show effective neutralization of the virus. However, people who had experienced COVID-19 before exhibiting stronger antibody levels and neutralizing activity against both BA.1 and BA.2. Additionally, the analysis of immune cells' gene expression demonstrates distinct immune responses and antibody production patterns between BA.1 and BA.2 patients. Overall, the immune response to Omicron variant, especially BA.2, is significantly influenced by individuals' previous infection history.
Systems vaccinology of mRNA and vector-based vaccines in healthy individuals and patients with immunological disorders
In December 2020, the U.S. Food and Drug Administration issued the first emergency use authorization (EUA) for a vaccine for the prevention of COVID-19 caused by SARS-CoV-2. There was an urgent need to understand the immune response mounted in different population groups, young versus old and the response of individuals that had been previously infected. Equally, and maybe even more critical, is an understanding of the immune response in immunocompromised individuals, such as cancer and organ transplant patients. For this, we initiated studies with partners in Austria, Italy, Germany and South Korea.
Adult-onset Stills disease (AOSD) patients are a group that might experience disease flare due to vaccination, including COVID-19 vaccination. Limited information exists about the effectiveness of COVID-19 vaccination in this population. The decision to vaccinate these patients involves balancing safety and efficacy. Previous reports have indicated that AOSD patients can have disease flare after COVID-19 vaccination, but no study has investigated their immune transcriptional response and antibody production. Our study (PMID: 35532082) examines a 58-year-old male with AOSD who experienced a mild flare after the second dose of the BNT162b2 vaccine. The research evaluates the patient's clinical progression, immune transcriptional response, and antibody levels, including neutralization activity, following vaccination. We reported an elevated immune response and high anti-Omicron-spike neutralizing activity in adult-onset Stills disease patient immunized with BNT162b2 (PMID: 35532082).
Immune response of leukemia patients to COVID-19 vaccination
Patients with chronic lymphocytic leukemia (CLL) undergoing treatment with B-cell pathway inhibitors and anti-CD20 antibodies often have low immune responses to SARS-CoV-2 vaccination. To understand this, we examined 15 CLL/small lymphocytic lymphoma patients who received heterologous BNT162b2/ChAdOx1 vaccination (PMID: 36630562). After two doses, the antibody response rate was 40%, rising to 53% after a booster dose. Patients on Bruton tyrosine kinase inhibitor (BTKi) and venetoclax anti-CD20 antibody within 12 months of vaccination showed weaker responses compared to those on BTKi alone. T-cell responses were robust, with a 2-dose-T-cell response rate of 80%, increasing to 93% with the booster. Transcriptional analysis revealed rapid interferon-mediated signaling activation, unrelated to antibody response magnitude. Higher counts of IGHV genes were linked to improved B-cell recovery and better antibody response. T-cell responses seemed unaffected by treatment status, while better antibody responses were associated with BTKi treatment and B-cell recovery. Boosting was especially effective when the patients' immune status improved due to CLL treatment.
In this reporting period we made progress in developing computational tools that permit the identification of transcriptional changes induced by specific viral variants (PMID: 38307916). Bulk RNA sequencing (RNA-seq) of blood is typically used for gene expression analysis in biomedical research but is still rarely used in clinical practice. In this study, we propose that RNA-seq should be considered a diagnostic tool, as it offers not only insights into aberrant gene expression and splicing but also delivers additional readouts on immune cell type composition as well as B-cell and T-cell receptor (BCR/TCR) repertoires. We demonstrate that RNA-seq offers insights into a patient's immune status via integrative analysis of RNA-seq data from patients infected with various SARS-CoV-2 variants (in total 196 samples with up to 200 million reads sequencing depth). We compare the results of computational cell-type deconvolution methods (e.g., MCP-counter, xCell, EPIC, quanTIseq) to complete blood count data, the current gold standard in clinical practice. We observe varying levels of lymphocyte depletion and significant differences in neutrophil levels between SARS-CoV-2 variants. Additionally, we identify B and T cell receptor (BCR/TCR) sequences using the tools MiXCR and TRUST4 to show that-combined with sequence alignments and BLASTp-they could be used to classify a patient's disease. Finally, we investigated the sequencing depth required for such analyses and concluded that 10 million reads per sample is sufficient. In conclusion, our study reveals that computational cell-type deconvolution and BCR/TCR methods using bulk RNA-seq analyses can supplement missing CBC data and offer insights into immune responses, disease severity, and pathogen-specific immunity, all achievable with a sequencing depth of 10 million reads per sample.
Terms: <2019 novel corona virus><2019 novel coronavirus><2019-nCoV><2019-nCoV variant><2019-nCoV variant forms><2019-nCoV variant strains><ACE2><Ab response><Address><Adult-Onset Still's Disease><Affect><Agammaglobulinaemia tyrosine kinase><Alternate Splicing><Alternative RNA Splicing><Alternative Splicing><Anti-CD20 Antibody><Antibodies><Antibody Formation><Antibody Production><Antibody Response><Austria><B blood cells><B cell><B cell progenitor kinase><B cells><B-Cell CLL><B-Cell Chronic Lymphocytic Leukemia><B-Cell Chronic Lymphogenous Leukemia><B-Cell Chronic Lymphoid Leukemia><B-Cell Lymphocytic Leukemia><B-Cells><B-Lymphocytes><B-Lymphocytic Leukemia><B-cell><B.1.1.529><BNT 162b2><BNT162b2><Biomedical Research><Blood><Blood Neutrophil><Blood Polymorphonuclear Neutrophil><Blood Reticuloendothelial System><Blood Sample><Blood specimen><Bruton's tyrosine kinase><CLL Lymphoplasmacytoid Lymphoma><COVID crisis><COVID epidemic><COVID infected patient><COVID pandemic><COVID patient><COVID positive patient><COVID-19><COVID-19 crisis><COVID-19 epidemic><COVID-19 era><COVID-19 exposure><COVID-19 global health crisis><COVID-19 global pandemic><COVID-19 health crisis><COVID-19 immune response><COVID-19 infected patient><COVID-19 infection><COVID-19 pandemic><COVID-19 patient><COVID-19 period><COVID-19 positive patient><COVID-19 prevention><COVID-19 public health crisis><COVID-19 vaccination><COVID-19 variant><COVID-19 variant forms><COVID-19 variant strains><COVID-19 virus><COVID-19 virus infection><COVID-19 years><COVID19 infection><COVID19 patient><COVID19 positive patient><COVID19 virus><CV-19><Cell Body><Cell Communication and Signaling><Cell Signaling><Cells><Chronic B-Lymphocytic Leukemia><Chronic Lymphatic Leukemia><Chronic Lymphoblastic Leukemia><Chronic Lymphocytic Leukemia><Chronic Lymphogenous Leukemia><Classification><Clinical><Clinical Research><Clinical Study><CoV-2><CoV2><Complete Blood Count><Computational toolkit><Coronavirus Infectious Disease 2019><Data><Disease><Disorder><Dose><Effectiveness><Europe><Event><Exhibits><FDA EUA><FDA Emergency Use Authorization><Flare><Food and Drug Administration><Food and Drug Administration EUA><Food and Drug Administration Emergency Use Authorization><Gene Expression><Gene Expression Monitoring><Gene Expression Pattern Analysis><Gene Expression Profiling><Gene Splicing><Gene Transcription><Genes><Genetic Alteration><Genetic Change><Genetic Transcription><Genetic defect><Germany><History><Human><IFN><Immune><Immune Cell Activation><Immune Diseases><Immune Disorders><Immune Dysfunction><Immune System Diseases><Immune System Disorder><Immune System Dysfunction><Immune System and Related Disorders><Immune response><Immune system><Immunes><Immunity><Immunize><Immunochemical Immunologic><Immunocompromised><Immunocompromised Host><Immunocompromised Patient><Immunodeficiency and Immunosuppression Disorders><Immunologic><Immunologic Diseases><Immunological><Immunological Diseases><Immunological Dysfunction><Immunological System Dysfunction><Immunological response><Immunologically><Immunologics><Immunosuppressed Host><In Vitro><Individual><Infection><Inflammation><Inflammatory Response><Interferons><International><Intracellular Communication and Signaling><Italy><JAK kinase><Janus kinase><Kidney><Kidney Urinary System><Link><Logistics><Lung><Lung Respiratory System><Lymphocyte Depletion><Lymphocytic Lymphoma><Lymphoma, Lymphocytic, Plasmacytoid><Lymphoma, Lymphocytic, Well-Differentiated><MHC Receptor><Major Histocompatibility Complex Receptor><Marrow Neutrophil><Mediating><Messenger RNA><Methods><Mice><Mice Mammals><MoAb Anti-B1><Modern Man><Monoclonal Antibody Anti-B1><Murine><Mus><Mutation><Neutrophilic Granulocyte><Neutrophilic Leukocyte><Omicron variant><PTK Inhibitors><Pathway interactions><Patients><Pattern><Persons><Pfizer covid19 vaccine><Pfizer-BioNTech COVID-19 vaccine><Pfizer-BioNTech coronavirus disease 2019 vaccine><Pfizer/BioNTech vaccine><Polymorphonuclear Cell><Polymorphonuclear Leukocytes><Polymorphonuclear Neutrophils><Population><Population Group><Prevalence><Production><Protein Tyrosine Kinase Inhibitors><Publishing><RNA Expression><RNA Seq><RNA analysis><RNA sequencing><RNAseq><Receptor Protein><Recording of previous events><Recovery><Reporting><Republic of Korea><Research><SARS corona virus 2><SARS-CO-V2><SARS-COVID-2><SARS-CoV-2><SARS-CoV-2 B.1.1.529><SARS-CoV-2 epidemic><SARS-CoV-2 exposure><SARS-CoV-2 global health crisis><SARS-CoV-2 global pandemic><SARS-CoV-2 immune response><SARS-CoV-2 infected patient><SARS-CoV-2 infection><SARS-CoV-2 omicron><SARS-CoV-2 omicron variant><SARS-CoV-2 pandemic><SARS-CoV-2 patient><SARS-CoV-2 positive patient><SARS-CoV-2 vaccination><SARS-CoV-2 variant><SARS-CoV-2 variant forms><SARS-CoV-2 variant strains><SARS-CoV2><SARS-CoV2 exposure><SARS-CoV2 infection><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-coronavirus-2 epidemic><SARS-coronavirus-2 pandemic><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Safety><Sampling><Sequence Alignment><Severe Acute Respiratory Coronavirus 2><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome CoV 2 epidemic><Severe Acute Respiratory Syndrome CoV 2 pandemic><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 epidemic><Severe acute respiratory syndrome coronavirus 2 exposure><Severe acute respiratory syndrome coronavirus 2 immune response><Severe acute respiratory syndrome coronavirus 2 infection><Severe acute respiratory syndrome coronavirus 2 pandemic><Severe acute respiratory syndrome coronavirus 2 vaccination><Severe acute respiratory syndrome related corona virus 2><Severity of illness><Signal Pathway><Signal Transduction><Signal Transduction Systems><Signaling><Small B-Cell Lymphocytic Lymphoma><Small Cell Lymphoma><Small Lymphocytic Lymphoma><Small-Cell Lymphoma><South Korea><Spliced Genes><System><Systematics><T cell response><T-Cell Antigen Receptors><T-Cell Receptor><T-cell receptor repertoire><TCR repertoire><TK Inhibitors><Therapeutic Uses><Transcript Expression Analyses><Transcript Expression Analysis><Transcription><Tyrosine Kinase Inhibitor><USFDA><United States Food and Drug Administration><Vaccination><Vaccinee><Vaccines><Variant><Variation><Viral><Virus><Wuhan coronavirus><analyze gene expression><angiotensin converting enzyme 2><angiotensin converting enzyme II><anti-B1><antibody biosynthesis><biological signal transduction><booster dose><booster shot><booster vaccine><bpk protein><btk protein><cancer transplantation><cell type><chronic lymphoid leukemia><clinical practice><computational toolbox><computational tools><computational toolset><computerized tools><coronavirus disease 2019><coronavirus disease 2019 crisis><coronavirus disease 2019 epidemic><coronavirus disease 2019 exposure><coronavirus disease 2019 global health crisis><coronavirus disease 2019 global pandemic><coronavirus disease 2019 health crisis><coronavirus disease 2019 immune response><coronavirus disease 2019 infected patient><coronavirus disease 2019 infection><coronavirus disease 2019 pandemic><coronavirus disease 2019 patient><coronavirus disease 2019 positive patient><coronavirus disease 2019 prevention><coronavirus disease 2019 public health crisis><coronavirus disease 2019 vaccination><coronavirus disease 2019 variant><coronavirus disease 2019 variant forms><coronavirus disease 2019 variant strains><coronavirus disease 2019 virus><coronavirus disease crisis><coronavirus disease epidemic><coronavirus disease infected patient><coronavirus disease pandemic><coronavirus disease patient><coronavirus disease positive patient><coronavirus disease-19><coronavirus disease-19 global pandemic><coronavirus disease-19 pandemic><coronavirus disease-19 patient><coronavirus disease-19 prevention><coronavirus disease-19 virus><coronavirus infectious disease-19><coronavirus patient><cytokine release syndrome><cytokine storm><diagnostic tool><disease severity><emergency use authorization><experience><experiment><experimental research><experimental study><experiments><exposure to COVID-19><exposure to SARS-CoV-2><exposure to SARS-CoV2><exposure to Severe acute respiratory syndrome coronavirus 2><exposure to coronavirus disease 2019><gene expression analysis><gene expression assay><gene signatures><genetic signature><genome mutation><genome scale><genome-wide><genomewide><global gene expression><global transcription profile><hCoV19><histories><host response><immune activation><immune system response><immunoglobulin biosynthesis><immunological status><immunoresponse><immunosuppressed patient><improved><individual response><individualized response><infected with COVID-19><infected with COVID19><infected with SARS-CoV-2><infected with SARS-CoV2><infected with coronavirus disease 2019><infected with severe acute respiratory syndrome coronavirus 2><inhibiting antibody><inhibitor><insight><international partnership><international research partnership><kinase inhibitor><leukemia><leukemia treatment><leukemic therapy><lymphocyte depletion therapy><mRNA><male><nCoV2><neutralizing antibody><neutrophil><omicron variant of COVID-19><omicron variant of SARS-CoV-2><organ transplant patient><organ transplant recipient><pandemic><pandemic disease><pathogen><pathway><patient infected with COVID><patient infected with COVID-19><patient infected with SARS-CoV-2><patient infected with coronavirus disease><patient infected with coronavirus disease 2019><patient infected with severe acute respiratory syndrome coronavirus 2><patient with COVID><patient with COVID-19><patient with COVID19><patient with SARS-CoV-2><patient with coronavirus disease><patient with coronavirus disease 2019><patient with severe acute respiratory distress syndrome coronavirus 2><prevent COVID-19><prevent coronavirus disease 2019><pulmonary><receptor><receptor binding><receptor bound><renal><response><sequencing alignment><severe acute respiratory syndrome coronavirus 2 B.1.1.529><severe acute respiratory syndrome coronavirus 2 global health crisis><severe acute respiratory syndrome coronavirus 2 global pandemic><severe acute respiratory syndrome coronavirus 2 infected patient><severe acute respiratory syndrome coronavirus 2 patient><severe acute respiratory syndrome coronavirus 2 positive patient><severe acute respiratory syndrome coronavirus 2 variant><severe acute respiratory syndrome coronavirus 2 variant forms><severe acute respiratory syndrome coronavirus 2 variant strains><symptomatology><tool><tositumomab><transcriptional profiling><transcriptome><transcriptome sequencing><transcriptomic sequencing><vaccinate against COVID-19><vaccinate against SARS-CoV-2><vaccinate against coronavirus disease 2019><vaccinate against severe acute respiratory syndrome coronavirus 2><vaccinated individual><vaccinated participant><vaccinated patient><vaccinated person><vaccinated subject><vaccination against COVID-19><vaccination against SARS-CoV-2><vaccination against Severe acute respiratory syndrome coronavirus 2><vaccination against coronavirus disease 2019><vaccine boost><vaccinology><vector-based vaccine>